---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-350568"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-08-14T12:21:44+00:00"
generated_at: "2026-08-14T12:25:27.081949+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics Q2 2026: Net loss $75.5M, cash $116M, Orphai acquisition closed

## Summary
- Completed stock-for-stock Orphai acquisition adding LAM-001 inhaled rapamycin; concurrent $115M private placement, net $103.6M.
- Cash and equivalents $116M as of June 30, 2026, expected to fund operations through end of 2028.
- Net loss $75.5M ($12.31/share) vs $16.0M ($68.75/share) in Q2 2025; G&A up to $16.6M on one-time stock comp.
- Phase 2b PH-ILD data expected Q1 2028; BOS Phase 2 data Q1 2027; SAPH trial start late 2026.
- Phase 2a ATS data: 6MWD +67.4m, PVR -33.9% in PH-ILD patients; drug generally well tolerated.

## SEC filing metadata
- accession: 0001193125-26-350568
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-08-14T12:21:44+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/0001193125-26-350568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-350568
- JSON: https://secwatch.observer/filing/0001193125-26-350568.json
- Plain text: https://secwatch.observer/filing/0001193125-26-350568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.